Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel to Discuss Sanofi’s Antiepileptic Drug Vigabatrin on Feb. 24
February 16, 2016
- MHLW Advisory Committee to Discuss 2 Lung Cancer Drugs on Feb. 26
February 16, 2016
- 3 Regenerative Medicine Products, 2 Medical Devices Designated for Sakigake Review: MHLW
February 15, 2016
- Chuikyo OKs Basic Plan for Pilot-Based HTA Scheme; Sovaldi, Opdivo Emerge as Likely Candidates
February 12, 2016
- Chuikyo Submits Recommendation for FY2016 Reimbursement Policy Reform, New Generic Incentive for Clinics Already Questioned
February 12, 2016
- Working Group Debate Kicks Off toward Realizing New Ryukaikon Proposal
February 12, 2016
- MHLW Sends Alert on Kids’ Accidental Ingestion of Psychotropics, Other Drugs
February 10, 2016
- Frequency of Drug Price Revisions to Be Discussed by Chuikyo: Govt
February 8, 2016
- MHLW Panel Supports Pain Indication for Cymbalta by Majority Vote
February 8, 2016
- Hep B Vaccines to Join Public Immunization Program in October
February 8, 2016
- Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
February 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for January
February 5, 2016
- MHLW Won’t Rule Out Single-Patient Humanitarian Trials: Official
February 5, 2016
- Council OKs Public Knowledge-Based Application for Capecitabine as Adjuvant Chemotherapy for Rectal Cancer
February 5, 2016
- Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation
February 4, 2016
- NCC, PMDA Forge Comprehensive Collaboration Pact
February 3, 2016
- MHLW Panel Backs Approval of Novartis’s Melanoma Drugs
February 2, 2016
- MHLW Allows Shipment of Kaketsuken’s Hep A, B Vaccines
February 2, 2016
- Chuikyo Reps Want Price-Based Penalty Added to Supplementary Opinions for FY2016 Reform Proposal, MHLW Expresses Caution
February 1, 2016
- Govt Says It’s “Not Recommending” Research-Driven Makers to Become Generic Makers, It’s One Option
February 1, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…